Please login to the form below

Not currently logged in
Email:
Password:

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio file ide-cel CAR-T for multiple myeloma in US

BMS and bluebird bio file ide-cel CAR-T for multiple myeloma in US

BMS has already claimed approval for multiple sclerosis therapy Zeposia (ozanimod), the first of the three, while the second – lisocabtagene maraleucel or liso-cel for lymphoma – is under regulatory review.

Latest news

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics